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Background: Esophageal cancer is the sixth leading cause of cancer death worldwide; current early detection
screening tests are inadequate. Esophageal balloon cytology successfully retrieves exfoliated and scraped superficial
esophageal epithelial cells, but cytologic reading of these cells has poor sensitivity and specificity for detecting
esophageal squamous dysplasia (ESD), the precursor lesion of esophageal squamous cell carcinoma (ESCC).
Measuring telomere length, a marker for chromosomal instability, may improve the utility of balloon cytology for
detecting ESD and early ESCC.
Methods: We examined balloon cytology specimens from 89 asymptomatic cases of ESD (37 low-grade and 52
high-grade) and 92 age- and sex-matched normal controls from an esophageal cancer early detection screening study.
All subjects also underwent endoscopy and biopsy, and ESD was diagnosed histopathologically. DNA was extracted from
the balloon cytology cells, and telomere length was measured by quantitative PCR. A receiver operating characteristic
(ROC) curve was plotted for telomere length as a diagnostic marker for high-grade dysplasia.
Results: Telomere lengths were comparable among the low- and high-grade dysplasia cases and controls, with means
of 0.96, 0.96, and 0.92, respectively. The area under the ROC curve was 0.55 for telomere length as a diagnostic marker
for high-grade dysplasia. Further adjustment for subject characteristics, including sex, age, smoking, drinking, hyperten-
sion, and body mass index did not improve the use of telomere length as a marker for ESD.
Conclusions: Telomere length of esophageal balloon cytology cells was not associated with ESCC precursor lesions.
Therefore, telomere length shows little promise as an early detection marker for ESCC in esophageal balloon samples.
Keywords: Esophageal squamous cell carcinoma, Esophageal squamous dysplasia, Early detection, Screening, Balloon
cytology, TelomeresBackground
Esophageal cancer is the 6th leading cause of cancer
death worldwide and was estimated to have killed 406,800
people in 2008 [1]. Over 80% of esophageal cancer cases
and deaths occur in developing countries [1], and in these
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stated.carcinoma (ESCC) [1,2]. Esophageal cancers can be suc-
cessfully treated if diagnosed early [3], but tumors are usu-
ally asymptomatic until they reach an advanced stage,
when they are much more difficult to cure. In the United
States, the overall 5-year relative survival rate for esopha-
geal cancer is 19% [4], but in low-resource populations, in
which most esophageal cancer cases occur, the survival
rate may be as low as 3% [5]. Asymptomatic patients with
precursor lesions can be treated to prevent progression to
invasive tumors and death [6,7], but current screening
tests for precursor lesions are inadequate.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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central China, which includes the county of Linxian [8].
Previous studies by our group in this region have shown
that esophageal squamous dysplasia (ESD) is the clinic-
ally relevant precursor lesion of ESCC [9,10] and that
ESD can be accurately identified with the use of Lugol’s
iodine staining during endoscopy and confirmed with
biopsy [11]. However, endoscopy is time-consuming, in-
vasive, and also requires specially trained personnel and
equipment to perform the examination, take biopsies,
and make appropriate pathologic diagnoses, so frequent
endoscopy for ESCC early detection screening in high-
risk asymptomatic populations in underdeveloped set-
tings with inadequate health resources remains a major
challenge [12].
Balloon cytology, a simple and inexpensive method
of retrieving esophageal cells, has been commonly used
in China for diagnosing patients with dysphagia or for
screening asymptomatic, high-risk populations for esopha-
geal cancer [13]. In our previous studies, balloon cytology
using traditional cytologic examination had poor sensitiv-
ity and specificity for detecting ESD [14,15]. Thus, if a bio-
marker of esophageal disease that could be measured in
the balloon cytology cells could improve the sensitivity
and specificity of this cell collection technique for detect-
ing ESD, it might make an important public health impact.
A validated early detection marker for ESD might also
eventually serve as a target for the future development of
inexpensive and rapid point-of-care molecular diagnostics
that could be used to augment balloon cytology in
resource-limited locations.
One hypothesized biomarker of neoplastic disease is
telomere length. Telomeres are regions of repetitive nu-
cleotide sequence at the ends of chromosomes that protect
these ends from deterioration or fusion with neighboring
chromosomes [16]. Chromosome replication during cell
division results in telomere shortening. In the absence of
the telomerase reverse transcriptase enzyme, which main-
tains telomere length, cells undergo replicative senescence.
Thus, telomere length and the restriction of telomerase
activity may play important roles in the prevention of
uncontrolled cell division [17]. Telomere dysfunction or
shortening is a common, and often early, genetic alteration
acquired in a cancer [18]. Telomere length may serve as a
marker of both chromosomal instability and cancer devel-
opment [19].
Previous work has found that telomere length is asso-
ciated with cancer incidence and mortality [20]. Several
studies have examined the association between telomere
length and neoplastic progression, including studies of
biliary tract [21], colon [22-24], lung [25], and prostate
[26] cancer. Telomere length abnormalities have been
found to occur early in the initiation of epithelial carcino-
genesis and may be an initiating event in many humanepithelial cancers [27]. Shortened telomeres have been
found in cancer cells isolated from paraffin-embedded sec-
tions of ESCC tumor biopsies [28]. Furthermore, patients
who underwent esophageal resection as a result of ESCC
had shorter telomeres in their tumors relative to their
nearby non-neoplastic esophageal epithelial cells. How-
ever, it is particularly important to note that both the
tumor and the nearby non-neoplastic esophageal epithelial
cell types from cancer patients had shorter telomere
lengths than the cells collected from non-cancer individ-
uals with normal esophageal epithelium, suggesting a
telomere-shortened epithelial field in the cancer patients
[29]. In addition to studies in ESCC, some other studies
have focused on individuals with Barrett’s esophagus, who
are at increased risk of esophageal adenocarcinoma,
another type of esophageal cancer. Tissue biopsies of
Barrett’s esophagus, the premalignant condition that is
linked to the development of esophageal adenocarcinoma,
have displayed shortened telomeres [30], and shorter blood
leukocyte telomere length among Barrett’s esophagus pa-
tients has been associated with an increased risk of future
esophageal adenocarcinoma [31]. Another study suggested
that chromosome-specific telomere length in blood cells
may be related to esophageal cancer [32].
Given the evidence that ESCC tumor cells may have
shortened telomeres and given that non-malignant esopha-
geal epithelial cells from cancer patients have shorter
telomeres compared with normal esophageal cells from
non-cancer patients (suggesting a telomere-shortened
epithelial field in the cancer patients) [29], we aimed to
examine the telomere length of DNA extracted from
balloon cytology-collected esophageal cells as a potential
early detection biomarker for ESD, the histologic precur-
sor of ESCC. These cells were collected from high-risk




The participants were recruited from a commune in
Linxian, China, in the spring of 2002, as part of a cancer
screening study using esophageal balloon cytology (Cy-
tology Sampling Study 2), as previously described [15].
Briefly, the study targeted healthy residents aged 50- to
64-years old, although approximately 10% of the 720
participating individuals fell outside of that age range.
Individuals who had any signs or symptoms of upper
gastrointestinal (GI) cancer (dysphagia, hematemesis) or
other chronic diseases (liver cirrhosis, congestive heart
failure, unstable angina) were excluded from the study.
All subjects completed a written informed consent and
a short questionnaire and physical exam prior to the
esophageal cancer screening procedures. The study was
approved by the Institutional Review Boards of the Cancer
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the U.S. National Cancer Institute.
Balloon cytology
All subjects fasted overnight prior to the balloon cy-
tology exam and were randomly assigned one of two
esophageal balloon cytology retrieval devices, as previ-
ously described [15]. The samples used in the present
study were all collected using an expandable balloon with
a plastic mesh covering (Cytomesh Esophageal Cytology
Device, Wilson-Cook Medical, Inc., Winston-Salem, North
Carolina, USA). The patient was given 2 ml of a 2% lido-
caine slurry by mouth for local anesthesia, and the balloon
was inserted into the back of the throat and swallowed.
Once in the stomach, the balloon and mesh covering were
expanded with 7–10 mL of air and gradually withdrawn
through the esophagus. The balloon, along with its col-
lected cells from the stomach, the full length of the
esophagus, and the oral cavity, was cut using sterile scis-
sors and placed in 40 mL of saline in a 50-mL centrifuge
tube, shaken, and transferred on ice to the central process-
ing laboratory. The sample was then vortexed to remove
adherent cells from the balloon. After the balloon was re-
moved, the remaining sample was centrifuged at 1500
RPM for 5 minutes; the pellet that formed was resus-
pended in 1 mL of saline and snap frozen in liquid nitro-
gen and stored at −80°C until DNA extraction.
Endoscopic examination
Two weeks after the balloon cytology, all subjects under-
went endoscopy to examine the esophagus and stomach.
After fasting overnight, the subjects were given 5 mL of
a 1% lidocaine slurry by mouth for local anesthesia 2–
5 minutes prior to endoscopy, which was performed
using a Pentax EG-2930 or EG-2731 videoendoscope
(Pentax Medical Company, Montvale, New Jersey, USA).
Glycerin-free Lugol’s iodine solution was sprayed from
the gastroesophageal junction to the upper esophageal
sphincter. All visible lesions and Lugol’s-unstained areas
in the esophagus and at least 1 normally stained mideso-
phageal site were biopsied. The endoscopic biopsy slides
were read using criteria previously described [33,34].
DNA extraction
The Gentra Puregene Cell kit (Qiagen, Valencia, CA) was
used according to the manufacturer’s instructions to ex-
tract the DNA from 300 ul of the cell suspension. The
DNA quality and quantity was checked using the 260:280
ratio, Nanodrop, and Picogreen.
Study design
We used a nested case–control design and selected sub-
jects who had undergone both balloon cytology and endos-
copy. We selected all of the subjects who had squamousdysplasia as their worst biopsy diagnosis: 38 cases of mild
dysplasia, 38 cases of moderate dysplasia, and 17 cases of
severe dysplasia. We then selected 94 normal controls who
were matched to the squamous dysplasia cases based on
age (within 5 years) and sex. In addition, we selected 50
cases of esophagitis that were matched based on age
(within 5 years) and sex to the already selected controls.
Telomere length measurement
Telomere length of the DNA samples was measured by
quantitative PCR [31,35]. Each sample (200 ng) was
amplified for telomeric DNA and for 36B4, a single-copy
control gene, which was used as an internal control to
normalize the starting amount of DNA. PCR reactions
were set up with a Qiagility pipetting robot and were
performed in a Rotor Gene Q (Qiagen, Valencia, CA).
Samples were run in batches of 24, with each batch in-
cluding 2 or 3 randomly inserted quality control samples,
which came from a pool of 5 endoscopically normal sub-
jects not selected for this study. Two additional controls
were used for normalization between experiments. Peri-
odic reproducibility experiments were performed to con-
firm adequate normalization. All samples, standards, and
controls were run in triplicate, and the median value was
used for the analyses. A standard curve was used to trans-
form the cycle threshold into nanograms of DNA. The
amount of telomeric DNA (T) was divided by the amount
of single-copy control gene DNA (S), producing a relative
measurement of the telomere length (T/S ratio). The coef-
ficient of variation for the quantitative PCR across all
batches was 8.5%.
Covariates
The following baseline characteristics of the subjects
were included in the analysis: age in years, body mass
index (BMI, kg/m2) from measured height and weight,
tobacco smoking (ever versus never), alcohol drinking
(any in the past 12 months versus none), and hyperten-
sion (measured systolic blood pressure over 140 mm Hg
or diastolic blood pressure over 90 mm Hg).
Statistical analysis
Some of the selected subjects did not have sufficient
DNA for telomere length measurement, so in our final
analysis we had data available from 50 cases of esophagitis,
37 cases of mild dysplasia, 37 cases of moderate dysplasia,
15 cases of severe dysplasia, and 92 normal controls. Low-
grade dysplasia was synonymous with mild dysplasia,
while high-grade dysplasia combined the 37 cases of mod-
erate dysplasia and 15 cases of severe dysplasia into one
category. Given the number of cases and controls, we had
80% power to detect a statistically significant difference of
0.10 in telomere length between the groups.











Males, N (%) 43 (47) 12 (24) 17 (46) 16 (43) 7 (47)
Age, median years (Q1-Q3) 54 (51–57) 53 (51–57) 54 (51–58) 55 (53–57) 55 (52–57)
BMI, median (Q1-Q3) 23.5 (21.5-24.8) 23.2 (21.8-25.4) 23.1 (20.8-25.2) 22.7 (20.4-24.8) 24.5 (22.5-27.2)
Ever smoke cigarettes, N (%) 28 (30) 11 (22) 10 (27) 11 (30) 5 (33)
Drink alcohol, any, N (%) 11 (12) 2 (4) 2 (5) 2 (5) 1 (7)
Hypertension, yes, N (%) 64 (68) 34 (68) 30 (81) 27 (73) 11 (73)
Telomere lengtha, mean (SD) 0.92 (0.17) 0.90 (0.16) 0.96 (0.18) 0.95 (0.17) 0.97 (0.24)
Telomere lengtha, median (Q1-Q3)a 0.92 (0.78-1.05) 0.88 (0.80-1.00) 0.93 (0.84-1.06) 0.94 (0.82-1.09) 0.93 (0.85-0.98)
aCalculated as telomeric DNA (T) divided by amount of single-copy control gene DNA (S) to produce the relative measurement of telomere length (T/S ratio).
Abbreviations: SD, standard deviation; Q1, first quartile; Q3, third quartile; BMI, body mass index.
Table 2 Telomere lengtha by selected subject characteristics
among the normal controls
Characteristics N Mean SD Q1 Median Q3 p
Sex
Males 43 0.91 0.17 0.78 0.92 1.03
Females 49 0.94 0.18 0.79 0.94 1.06 0.51
Age
<54 years 45 0.94 0.18 0.80 0.94 1.06
≥54 years 47 0.91 0.17 0.80 0.89 1.04 0.36
BMI
<18.5 2 0.89 - 0.83 0.89 0.95
18.5 - <23 40 0.92 0.18 0.75 0.92 1.04
23 - <27.5 46 0.94 0.17 0.80 0.93 1.06
≥27.5 4 0.94 0.18 0.82 0.94 1.06 0.78
Smoke tobacco
Ever 28 0.89 0.17 0.77 0.90 0.97
Never 64 0.94 0.18 0.79 0.95 1.06 0.21
Drink alcohol
Any 11 0.94 0.13 0.89 0.95 1.04
None 81 0.92 0.18 0.78 0.91 1.05 0.65
Hypertension
Yes 63 0.92 0.17 0.77 0.90 1.04
No 29 0.94 0.18 0.84 0.95 1.06 0.36
aCalculated as telomeric DNA (T) divided by amount of single-copy control gene
DNA (S) to produce the relative measurement of telomere length (T/S ratio).
Abbreviations: SD, standard deviation; Q1, first quartile; Q3, third quartile; BMI,
body mass index.
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sessed for normality, and we found no evidence for devi-
ation from a normal distribution. Telomere length was
treated as a continuous variable and as quartiles based on
the distribution in controls. The Wilcoxon exact test and
the analysis of variance (ANOVA) were used to compare
telomere length by subject characteristics. A receiver oper-
ating characteristic (ROC) curve was plotted for the use
of telomere length as a diagnostic marker for high-grade
dysplasia. The association between telomere length (scaled
by half of the interquartile range or as quartiles) and the
worst biopsy diagnosis was assessed using unconditional
logistic regression models. Adjusted models included age,
sex, BMI, tobacco smoking, alcohol use, and hypertension.
All tests were two-sided, and p-values <0.05 and confi-
dence intervals (CI) that did not overlap with 1.00 were
considered statistically significant. SAS 9.2 was used for
statistical analyses, and GraphPad Prism 5 was used for
the ROC analysis.
Results
The characteristics for the subjects chosen for this study
are shown in Table 1. More women than men were se-
lected. Compared with the other groups, the severe dys-
plasia cases had a slightly higher BMI and were more
likely to smoke tobacco. In this population, those who
reported smoking tobacco were almost exclusively male.
Alcohol intake was relatively rare in this population. The
mean telomere lengths among the normal controls (0.92)
and the esophagitis (0.90) and mild (0.96), moderate (0.95),
and severe dysplasia (0.97) cases were similar (p = 0.542).
For further analyses, we dichotomized the dysplasia cases
by categorizing the mild dysplasia cases as low-grade dys-
plasia and combining the moderate and severe dysplasia
cases into one category of high-grade dysplasia (this com-
bined high-grade dysplasia group had a mean telomere
length of 0.96, 95% CI 0.90-1.01).
Table 2 shows the distribution of telomere lengths among
the controls by select subject characteristics. Telomerelength did not significantly differ across any of these subject
characteristics.
Figure 1 shows the ROC curve for the use of telomere
length as a diagnostic marker for high-grade dysplasia. The
area under the curve was 0.55, suggesting that telomere
length of esophageal cells collected by balloon cytology is a
poor marker of the presence of high-grade dysplasia.
We further assessed the association between telomere
length and worst biopsy diagnosis, as shown in Table 3.
Figure 1 Receiver operating characteristic (ROC) curve plotted
for the use of telomere length as a diagnostic marker for
high-grade dysplasia (area under the curve = 0.55).
Lin et al. BMC Cancer 2013, 13:578 Page 5 of 8
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or as quartiles, was not associated with esophagitis, low-
grade dysplasia, or high-grade dysplasia. Adjusting for mul-
tiple potential confounders did not change the estimates.
Table 4 shows the unconditional logistic regression
models, both crude and adjusted, for risk of high-grade
dysplasia by telomere length. Again, no associations were
observed.Table 3 Associations between telomere lengtha and worst bio
Esophagitis
Controls Cases OR (95% CI)
Unadjusted
Continuousd 92 50 0.90 (0.68-1.18)
Quartiles
<0.784 23 10 ref
0.784 - <0.925 23 24 2.40 (0.94-6.13)
0.925 - <1.047 23 5 0.50 (0.15-1.69)
≥1.047 23 11 1.10 (0.39-3.09)
p-trend 0.031
Adjustede
Continuousd 92 50 0.91 (0.68-1.21)
Quartiles
<0.784 23 10 ref
0.784 - <0.925 23 24 2.46 (0.89-6.80)
0.925 - <1.047 23 5 0.59 (0.16-2.13)
≥1.047 23 11 1.08 (0.36-3.28)
p-trend 0.060
aCalculated as telomeric DNA (T) divided by amount of single-copy control gene DN
bLow-grade dysplasia category includes mild dysplasia cases.
cHigh-grade dysplasia category includes moderate and severe dysplasia cases.
dContinuous telomere length scaled by half the interquartile range based on the di
eModels adjusted for age, sex, BMI, tobacco smoking, alcohol drinking, and hyperte
Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index.Discussion
ESCC is generally diagnosed at a late stage and has a
very poor prognosis, so improving the methods of early
detection for these cancers is both urgent and of great
public health importance. We previously found that eso-
phageal balloon cytology had low sensitivity and specificity
for detecting the high-grade dysplastic lesions that are
likely to progress to ESCC [14,15]. Telomere length abnor-
malities, which are linked to genomic stability and risk of
cancer [19], have been found in ESCC [28], epithelial pre-
cursor lesions of multiple cancers [27], and, most import-
ant for the current study, in the broader non-malignant
epithelial field from which squamous cell carcinomas of
the esophagus arise [29]. Thus, we aimed to examine
whether analysis of telomere length from esophageal bal-
loon cytology samples could be used as an early detection
screening tool. However, in this study, we found that
telomere length of the esophageal cells collected by this
method was not associated with the presence of low- or
high-grade dysplasia in the patients, so the telomere length
of such cells could not be used to identify individuals with
esophageal precursor lesions who should subsequently
undergo endoscopy for confirmation and treatment or
follow-up of their lesions.
Most previous studies of telomere length in cancer have
measured telomeres in peripheral blood lymphocytes orpsy diagnosis
Low-grade dysplasiab High-grade dysplasiac
Cases OR (95% CI) Cases OR (95% CI)
37 1.14 (0.86-1.51) 52 1.14 (0.89-1.46)
4 ref 10 ref
14 3.50 (1.00-12.25) 14 1.40 (0.52-3.79)
9 2.25 (0.61-8.36) 13 1.30 (0.48-3.56)
10 2.50 (0.68-9.13) 15 1.50 (0.56-4.03)
0.224 0.870
37 1.16 (0.87-1.54) 52 1.20 (0.92-1.56)
4 ref 10 ref
14 4.80 (1.26-18.35) 14 1.51 (0.54-4.24)
9 3.07 (0.78-12.06) 13 1.50 (0.52-4.27)
10 3.05 (0.80-11.66) 15 1.83 (0.65-5.12)
0.107 0.713
A (S) to produce the relative measurement of telomere length (T/S ratio).
stribution among the normal controls.
nsion.
Table 4 Association between telomere lengtha and





Cases OR (95% CI)
Unadjusted
Continuousd 179 52 1.14 (0.91-1.43)
Quartiles
<0.784 37 10 ref
0.784 - <0.925 61 14 0.85 (0.34-2.11)
0.925 - <1.047 37 13 1.30 (0.51-3.34)
≥1.047 44 15 1.26 (0.51-3.14)
p-trend 0.728
Adjustede
Continuousd 179 52 1.17 (0.93-1.37)
Quartiles
<0.784 37 10 ref
0.784 - <0.925 61 14 0.93 (0.36-2.37)
0.925 - <1.047 37 13 1.43 (0.55-3.76)
≥1.047 44 15 1.39 (0.55-3.54)
p-trend 0.684
aCalculated as telomeric DNA (T) divided by amount of single-copy control
gene DNA (S) to produce the relative measurement of telomere length
(T/S ratio).
bCategory includes normal controls, esophagitis cases, and mild dysplasia cases.
cHigh-grade dysplasia category includes moderate and severe dysplasia cases.
dContinuous telomere length scaled by half the interquartile range based on
the distribution among the normal controls.
eModels adjusted for age, sex, BMI, tobacco smoking, alcohol drinking,
and hypertension.
Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index.
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[28-30,36,37]. By contrast, our study measured telomere
length in cells collected by esophageal balloon cytology,
which was a mixture of cells from the full length of the
esophagus as well as some cells collected from the stom-
ach and the oral cavity. Previously, non-neoplastic esopha-
geal epithelial cells from ESCC patients were reported to
have shorter mean telomere length than esophageal cells
from non-cancer patients [29], suggesting the presence of
a telomere-shortened epithelial field that could potentially
be detected using balloon cytology or other analogous
methods. In the current study, however, we could detect
no difference in mean telomere length between partici-
pants with and without ESD. Differences between the
results of our study and the previous one may reflect
differences in methods, actual differences in telomere
lengths in “normal” cells adjacent to ESCC and “normal”
cells adjacent to ESD, and/or chance. In any case, an effect-
ive early detection biomarker in balloon cytology cell sam-
ples must be present in a broad carcinogen-altered field
and must be reproducible. Thus, while we previously
showed the feasibility of screening for telomerase activity insamples collected by esophageal balloon cytology [38], we
demonstrate here that telomere length itself cannot serve
as an early detection marker for ESD in these samples.
Our study had several limitations. We had a limited
number of cases with low-grade and high-grade dysplasia.
Moreover, we extracted DNA from cells collected by eso-
phageal balloon cytology samplers, so any focal (non-field)
differences in telomere length would have had to be large
to be detected. Future work may examine telomere length
in peripheral blood lymphocytes collected from individuals
with endoscopy and biopsy-diagnosed esophageal precursor
lesions.
However, our study also had several strengths, includ-
ing following many of the guidelines that facilitate the
development of biomarker-based screening tools suitable
for early detection of cancer [39]. We used samples from
a well-characterized patient population, and we included
asymptomatic and apparently healthy subjects with a full
spectrum of esophageal health, from normal control sub-
jects through esophagitis and mild, moderate, and severe
dysplasia. All of the subjects underwent the gold standard
exam for determining esophageal health (endoscopy with
Lugol’s staining and biopsy). In addition, the telomere
length assay used in this study, which had a low coefficient
of variation, used small amounts of DNA in a high-
throughput assay and had been used in a number of previ-
ous studies of cancers in the gastrointestinal tract [23,40],
including those conducted in Barrett’s esophagus and
esophageal adenocarcinoma patients [31].
This is the first study to evaluate telomere length mea-
sured in esophageal balloon cytology samples as an early
detection marker for esophageal precursor lesions.
Conclusions
In conclusion, we observed no associations between telo-
mere length in these samples and risk of low- or high-
grade dysplasia, so our study provides little support for
this approach.
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